Effect Of Kad‐1229, A Novel Hypoglycaemic Agent, On Plasma Glucose Levels After Meal Load In Type 2 Diabetic Rats

Abstract

1. The effects of KAD-1229 (a novel non-sulphonylurea agent), voglibose (an alpha-glucosidase inhibitor) and nateglinide (a non-sulphonylurea antihyperglycaemic agent) on hyperglycaemia induced by a meal load were assessed in diabetic rats. 2. KAD-1229 suppressed the increase in plasma glucose levels seen after a meal load and the area under the curve for plasma glucose levels (AUCglucose) up to 5 h after the meal load. 3. Voglibose also suppressed the increase in plasma glucose levels; however, a significant decrease in AUCglucose following voglibose was not observed. 4. Nateglinide suppressed the increase in plasma glucose levels at 30 min and 1 h after the meal load; however, plasma glucose levels was above control thereafter and the AUCglucose was not decreased. 5. The results indicate that KAD-1229 has an antihyperglycaemic effect and KAD-1229 is suggested to be a suitable agent for controlling post-prandial hyperglycaemia.

Sergliflozin, a Novel Selective Inhibitor of Low-Affinity Sodium Glucose Cotransporter (SGLT2), Validates the Critical Role of SGLT2 in Renal Glucose Reabsorption and Modulates Plasma Glucose Level

“…5A). Rapid-and short-acting insulin secretagogues or ␣-glucosidases have often been evaluated in mildly diabetic rats (i.e., rats with a degree of diabetes severity similar to that induced here (Ikenoue et al, 1997;Ichikawa et al, 2002). Sergliflozin provides a parallel to these antidiabetics as a way of improving postprandial hyperglycemia, at least in diabetic rats.…”

Characterization of the action of S 21403 (mitiglinide) on insulin secretion and biosynthesis in normal and diabetic β‐cells

“…plasma half‐life of the drug) are as important in determining the risk of hypoglycaemia. In vivo studies using nondiabetic Wistar and diabetic GK rats suggested that S 21403 (KAD‐1229) could be a suitable agent for controlling postprandial hyperglycaemia, since it was able to suppress the increase in plasma glucose seen after a meal load up to 5 h after the meal ( Ichikawa et al ., 2002 ). The drug was also effective when administered orally to diabetic dogs ( Misawa et al ., 2001 ).…”

Na+/H+ exchanger 3 blockade ameliorates type 2 diabetes mellitus via inhibition of sodium‐glucose co‐transporter 1‐mediated glucose absorption in the small intestine

“…Meanwhile, the present study showed that both acute and 8 weeks of S3226 treatment lowered the postprandial plasma glucose levels remarkably. This beneficial effect on postprandial glucose surges was also observed in other antidiabetic drugs, such as insulin secretagogues or glucosidases . Given that SGLT1 inhibition is known to be associated with prominent side effects, such as diarrhoea, dehydration and malabsorption, we also considered if similar side effects could arise after prolonged application of NHE3 inhibitors.…”